How to obtain the anti-cancer drug erdafitinib and its treatment mechanism

Erdafitinib (Erdafitinib ) is an important treatment option for patients seeking treatment for certain types of urothelial cancer. This targeted anti-cancer drug is specifically designed to treat advanced or metastatic urothelial cancer. Its mechanism is to fight cancer by inhibiting tyrosine kinase activity in tumor cells.

However, erdafitinib is not currently available in China, so patients cannot purchase it directly locally. If patients want to obtain original-quality drugs, the Hong Kong version of erdafitinib is the first choice for patients, but the price is higher, with a price tag of more than 20,000 yuan per box, and the purchase method is limited to pharmacies in Hong Kong, China. On the other hand, foreign generic drugs provide a more economical option. These generic drugs are mainly from Laos and Bangladesh. The price is relatively low, but the active ingredients are similar to the original drugs.

Urothelial cancer, a cancer that starts in the cells lining the bladder, urethra, or renal pelvis, may become resistant to traditional chemotherapy and radiation therapy. Erdafitinib is unique in that it inhibits the FGFR (fibroblast growth factor receptor) family of tyrosine kinases, whose abnormal activity is closely associated with the development of many cancers.

When chemotherapy is ineffective or intolerable to the patient, erdafitinib becomes an option for the treatment of urothelial cancer. Typically, before starting treatment, patients undergo genetic testing to determine whether their tumors have FGFR gene mutations, as this would affect the effectiveness of erdafitinib.

Clinical trials have shown that erdafitinib has significant anti-cancer effects in some patients. However, it is worth noting that this drug may also cause some side effects, such as dry mouth, fatigue, dehydration, and hand-foot syndrome. Therefore, when using erdafitinib, doctors will consider the patient's overall condition and closely monitor the patient's response during treatment.

Although erdafitinib is not currently available in China, it is still possible for patients to obtain this cutting-edge anti-cancer drug through international channels, adding hope to the fight against cancer.